Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Plonmarlimab (TJ003234) in Healthy Subjects
NCT03794180Phase 1Completed
- Sponsor
- I-Mab
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of plonmarlimab in rheumatoid arthritis (RA) (5 arms), sponsored by I-Mab. Primary endpoints: Safety Profile: AEs and Maximum Tolerated Dose. Started Mar 2019; status: completed.
02
Drugs
plonmarlimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03794180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794180.